The four first-line drugs and the second-line agents: whether each is bacteriostatic or bactericidal, what it targets, how it is used, its signature adverse effects, what to monitor and teach, and how it is eliminated or resisted. No doses.
| Drug | Static or cidal | Mechanism | Use | Key adverse effects | Monitoring and education | Elimination and resistance | Source |
|---|---|---|---|---|---|---|---|
| The regimen | — | Mycobacteria are acid-fast bacilli with a waxy mycolic acid coat; M. tuberculosis grows very slowly and can lie dormant, so drugs that act on cell division work less well | Two months of isoniazid, rifampin, ethambutol and pyrazinamide, then four months of isoniazid and rifampin; pulmonary 6 to 9 months, with HIV (human immunodeficiency virus) 9 to 12, complicated 18 to 24 | — | Never single agents in active disease | Isoniazid or rifampin resistance: treat 18 to 24 months | L11 slide 35 slide 34 slide 36 slide 46 |
| Isoniazid | Bacteriostatic for latent, bactericidal for dividing bacteria | Inhibits mycolic acid production (the waxy cell coat); activated by the bacterial catalase-peroxidase | Prophylaxis alone; active disease in combination | Peripheral neuritis (pyridoxine deficiency); hepatitis (more in alcoholics and with age); lupus-like syndrome; seizures, euphoria, psychosis, memory impairment | Give pyridoxine (vitamin B6); liver tests, especially with alcohol use or older age | 75 to 95 percent excreted as an acetylated metabolite (fast and slow acetylators); well absorbed, enters the central nervous system; resistance by mutation in the activating enzyme’s gene | L11 slide 37 slide 38 slide 39 slide 33 |
| Rifampin | Not stated | Inhibits DNA-dependent RNA polymerase by forming a complex with the enzyme (no effect on the human enzyme); a semi-synthetic rifamycin | Tuberculosis; meningococcal disease prophylaxis; endocarditis | Orange tears, sweat and urine; induces cytochrome P450 enzymes; jaundice, hepatitis; flu-like hypersensitivity (20 percent); gastrointestinal upset | Warn about the orange color; review interacting drugs (anticoagulants, contraceptives, digoxin, ketoconazole, theophylline) | Rarely used alone: tolerance develops rapidly | L11 slide 41 slide 42 slide 40 slide 33 |
| Ethambutol | Bacteriostatic | Mechanism unknown: inhibits mycolic acid incorporation into membranes; no effect on other bacteria; the weakened cell wall lets the other agents in | First two months of the four-drug start | Visual disturbances: decreased red-green discrimination and visual acuity; increased uric acid | Ask about vision and color perception | 75 percent excreted unchanged: adjust in renal disease; resistance develops quickly if used alone | L11 slide 43 slide 44 slide 33 |
| Pyrazinamide | Not stated | Converted to pyrazinoic acid, which lowers the pH so the bacteria cannot grow; enters macrophages; exact target unclear | Shortens the combined course; given in the first two months only | Hepatitis (15 percent); hyperuricemia in every patient (inhibits uric acid excretion) | Monitor liver enzymes; avoid in pregnancy | Limited to the first two months to avoid liver toxicity | L11 slide 45 slide 33 |
| Second-line agents | — | — | Resistance or drug intolerance: streptomycin, aminosalicylic acid, cycloserine, rifabutin, macrolides, quinolones, clofazimine (leprosy), linezolid | Streptomycin auditory and vestibular; aminosalicylic acid gastrointestinal; cycloserine central nervous system (psychosis, seizures) | Hearing and balance; stomach upset; mood and seizures | — | L11 slide 46 |